Search / Trial NCT00002157

Compassionate Use Study of Two Dose Levels of Thalidomide in Adults With HIV Wasting Syndrome

Launched by CELGENE CORPORATION · Aug 30, 2001

Trial Information

Current as of December 06, 2024

Completed

Keywords

Acquired Immunodeficiency Syndrome Cachexia Thalidomide

ClinConnect Summary

Patients are randomized to receive thalidomide at 1 of 2 doses for 12 weeks initially, with response assessed at weeks 2, 4, 8, and 12. Patients failing the low dose will be eligible to increase the dose to the higher dose. Treatment may continue indefinitely. After 12 weeks, patients continuing treatment are evaluated every 2 months for up to 6 additional months, then every 6 months thereafter.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria
  • Concurrent Medication:
  • Allowed:
  • Antiretroviral therapy.
  • Prophylaxis or treatment for opportunistic infection.
  • Patients must have:
  • HIV-associated wasting.
  • Prior Medication:
  • Allowed:
  • Prior enrollment on Celgene's placebo-controlled thalidomide study, provided patient meets specified criteria for not continuing on that study.

About Celgene Corporation

Celgene Corporation, a subsidiary of Bristol Myers Squibb, is a biopharmaceutical company dedicated to improving patient outcomes through innovative therapies for cancer and immune-mediated diseases. With a strong focus on research and development, Celgene leverages advanced science and cutting-edge technology to discover and commercialize transformative medicines. The company is committed to addressing unmet medical needs by conducting rigorous clinical trials and collaborating with healthcare professionals to deliver high-quality treatments. Celgene’s legacy of scientific excellence and patient-centered approach underscores its mission to enhance the lives of patients worldwide.

Locations

Warren, New Jersey, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials